Immunopharmacologic Monitoring of Therapeutic Serum Antibodies
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage for measurement of serum drug levels and anti-drug antibodies to guide management of biologic therapies, primarily for members receiving anti-TNF agents and select biologics; applies to BlueCross BlueShield of Tennessee members.
No material clinical or coverage changes in this revision.
Coverage Criteria and Limitations
Coverage criteria and denials
Coverage determinations:
applies to anti-TNF, vedolizumab, ustekinumab
examples listed in policy
explicit drug list in policy
Measurement of serum drug concentrations and/or anti-drug antibodies to guide biologic therapy is addressed as follows. For individuals with inflammatory bowel disease (IBD), testing for anti-TNF therapies, vedolizumab, or ustekinumab meets coverage criteria when performed once every two weeks. For all other situations not specifically covered for IBD, measurement of the serum drug level and/or antibodies to the drug does not meet coverage criteria for the listed products. The policy explicitly lists the following agents in its reimbursement and exclusion statements: adalimumab, certolizumab, etanercept, golimumab, infliximab (and infliximab biosimilars), rituximab, ustekinumab, and vedolizumab.
Drug and/or antibody concentration testing for anti-TNF therapies when used to treat conditions other than IBD (examples specifically cited in the policy include spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis) does not meet coverage criteria and therefore will be denied under this policy. Additionally, outside the IBD-specific allowance, measurement of serum drug levels and/or antibodies does not meet coverage criteria for adalimumab, certolizumab, etanercept, golimumab, infliximab and its listed biosimilars, rituximab, ustekinumab, and vedolizumab.
Procedure and Billing Codes
Coding and submission — billing guidance
Billing guidance: Report the most specific CPT/HCPCS code available. For proprietary assays (e.g., Procise ADL™), use the assigned CPT Category I/III or Proprietary codes (0514U, 0515U) when applicable; otherwise, report unlisted or miscellaneous codes (80299, 84999) only when no specific code exists. Ensure the claim includes documentation of the test name, manufacturer, method, and numeric result to support medical necessity and correct processing.
- Include documentation of assay name, manufacturer (e.g., ProciseDx Inc.), and numeric result (µg/mL) with the claim.
- Use 0514U for Procise ADL™ (adalimumab) quantitative assay when available; 0515U for infliximab quantitative assay.
- Do not substitute unlisted codes (80299, 84999) if a specific CPT/HCPCS code exists.
- Claims may require crosswalk justification when proprietary codes are billed; attach test method and clinical indication for benefit/regulatory alignment.
Provider Responsibilities and Authorization
Verify benefits and prior authorization before testing
Confirm benefit coverage and any prior authorization requirements before ordering or submitting claims for drug/antibody concentration testing; authorization requirements vary by the member's benefit plan.
Align requests with member benefits and government regulations
Coverage decisions must align with the individual's benefits at the time of request and conform to applicable state and federal regulations (e.g., LCDs/NCDs); when government policy conflicts with this policy, the government policy governs.
- Reference member benefits and applicable Medicare/Medicaid coverage determinations when submitting requests.
- Follow state or federal requirements if they conflict with this policy.
Denial risk: testing for non‑IBD indications
Requests for drug and/or antibody concentration testing for anti‑TNF therapies for conditions other than inflammatory bowel disease will be denied as not meeting coverage criteria.
- Examples of non‑IBD conditions specified include spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis.
- Testing for these indications is considered not medically necessary under this policy.
Clinical Background
Anti-drug antibodies are immune responses that can develop to therapeutic biologics and may reduce drug efficacy or contribute to loss of response. Therapeutic drug monitoring—measuring circulating drug concentrations and antibodies—has been proposed and studied particularly in IBD as a tool to manage loss of response and to guide dosing or switching of biologic therapy; however, the policy limits coverage of such testing primarily to IBD where evidence and clinical utility have been supported, and considers testing for many other indications not to meet coverage criteria.
Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.